How Sarepta Short Interest Is Adding to Its Gains
Analysts are beginning to flock to Sarepta after the company made news surrounding a meeting with the FDA, not to mention the enormous boost that shares are getting from short covering.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 264Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?
Johnson & Johnson has been working on its pharmaceuticals pipeline for a while, and plans on continuing to do so.
More Than a Billion People Smoke Tobacco
In a piece of news that should hearten the cigarette industry and send chills down the spines of world health officials, a new study claims that a billion adults smoke tobacco worldwide.
Is This the End of the Growth Phase for Intercept?
Investors are not too happy with Intercept Pharmaceuticals after it released the terms for its most recent clinical trial.
What This New Trial Means for Eleven Biotherapeutics
Eleven Biotherapeutics released its most recent clinical trial results, and its drug candidate did not meet either of its two co-primary endpoints.
The 5 Winners and Losers From ASCO Presentations
Investors, doctors and cancer patients are anxiously awaiting some of the key presentations and abstracts from the American Society of Clinical Oncology (ASCO) annual meeting.
AcelRX Takes Flight With New Department of Defense Contract
AcelRX announced that it entered into a contract with the U.S. Army Medical Research and Material Command within the Department of Defense. The contract is worth up to $17 million.
Analyst Issues 5 Potential Biotech Buyout Candidates
Cowen sees the potential for super-mergers in biotech, as well as a large group of smaller targets that may be in the sights of bigger companies now.
Are Problems at Orexigen Still Just Getting Started?
Orexigen Therapeutics shares plunge after termination of cardiovascular outcomes study of the obesity drug Contrave.
Why the DepoMed Drop Is a Gross Overreaction
ThinkstockSometimes, or lots of times, investors and markets take things a little too far. For instance, a stock might overreact, to the upside or downside, based on too much optimism or pessimism. The market…
Could This Speculative Biotech More Than Triple?
Oppenheimer sees an upside of about triple the current share price of Tokai Pharmaceuticals, based on what it has coming out in its pipeline.
Why This Study May Have Saved Pain Therapeutics
Pain Therapeutics has announced top-line results for an FDA Category 3 Human Abuse Potential Study with Remoxy Extended-Release Capsules CII.
Short Sellers Keep Strong Bets Against Big Pharma
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
4 Biotech Stocks Could Have Big Upside Before Russell Index Changes
Credit Suisse expects that biotech stocks will see the most promotions in the coming rebalance of the Russell Indexes.
Short Sellers Start to Get Nervous on Biotech
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.